| SC 13G/A | 2024-02-14 | EcoR1 Capital, LLC | Tempest Therapeutics, Inc. | - | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Rock Springs Capital Management LP | Tempest Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-09 | FMR LLC | Tempest Therapeutics, Inc. | 431,932 | 2.2% | EDGAR |
| SC 13D/A | 2024-02-08 | Versant Venture Capital VI, L.P. | Tempest Therapeutics, Inc. | 997,940 | 5.2% | EDGAR |
| SC 13D/A | 2023-11-09 | Versant Venture Capital VI, L.P. | Tempest Therapeutics, Inc. | 997,940 | 7.5% | EDGAR |
| SC 13G/A | 2023-02-14 | Rock Springs Capital Management LP | Tempest Therapeutics, Inc. | 823,654 | 7.8% | EDGAR |
| SC 13G | 2023-02-14 | EcoR1 Capital, LLC | Tempest Therapeutics, Inc. | 1,052,810 | 10.0% | EDGAR |
| SC 13D | 2022-05-09 | Versant Venture Capital VI, L.P. | Tempest Therapeutics, Inc. | 997,940 | 9.7% | EDGAR |
| SC 13G | 2022-02-17 | LAV Regulus Ltd | Tempest Therapeutics, Inc. | 153,744 | 2.2% | EDGAR |
| SC 13G/A | 2022-02-14 | CITADEL ADVISORS LLC | Tempest Therapeutics, Inc. | - | 0.0% | EDGAR |
| SC 13G/A | 2022-02-14 | ROCHE FINANCE LTD | Tempest Therapeutics, Inc. | 72,612 | 1.1% | EDGAR |
| SC 13G/A | 2022-02-14 | Ikarian Capital, LLC | Tempest Therapeutics, Inc. | 58,803 | 0.9% | EDGAR |
| SC 13G | 2022-02-11 | Versant Venture Capital VI, L.P. | Tempest Therapeutics, Inc. | 997,940 | 14.4% | EDGAR |
| SC 13G | 2022-01-03 | Rock Springs Capital Management LP | Tempest Therapeutics, Inc. | 823,654 | 11.5% | EDGAR |
| SC 13G/A | 2021-07-15 | Rock Springs Capital Management LP | Tempest Therapeutics, Inc. | 310,161 | 4.7% | EDGAR |
| SC 13G | 2021-07-08 | Rock Springs Capital Management LP | Tempest Therapeutics, Inc. | 642,155 | 9.7% | EDGAR |
| SC 13G | 2021-07-06 | FMR LLC | Tempest Therapeutics, Inc. | 647,898 | 9.8% | EDGAR |
| SC 13D/A | 2021-04-13 | New Enterprise Associates 15, L.P. | Millendo Therapeutics, Inc. | 1,766,407 | 9.3% | EDGAR |
| SC 13G | 2021-04-07 | Ikarian Capital, LLC | Millendo Therapeutics, Inc. | 1,348,021 | 7.1% | EDGAR |
| SC 13G | 2021-03-16 | CITADEL ADVISORS LLC | Millendo Therapeutics, Inc. | - | 4.1% | EDGAR |